Key result
Weighted gene co-expression network analysis identified MYH7 and FH as key diagnostic biomarkers for hypertrophic cardiomyopathy, with AUCs of 0.762 and 0.612, respectively.
Why the study?
To reveal the molecular mechanism underlying the pathogenesis of HCM and find new effective therapeutic strategies using a systematic biological approach.
Effect estimate: MYH7 AUC: 0.762; FH AUC: 0.612
p-value: p=<0.05
Bioinformatics analysis using WGCNA identified MYH7 and FH as key hub genes with high diagnostic value for hypertrophic cardiomyopathy.
Identified HCM modules are hypothesis-generating; leaves open clinical translation or therapeutic targeting.
OBJECTIVE: To reveal the molecular mechanism underlying the pathogenesis of HCM and find new effective therapeutic strategies using a systematic biological approach. METHODS: The WGCNA algorithm was applied to building the co-expression network of HCM samples. A sample cluster analysis was performed using the hclust tool and a co-expression module was constructed. The WGCNA algorithm was used to study the interactive connection between co-expression modules and draw a heat map to show the strength of interactions between modules. The genetic information of the respective modules was mapped to the associated GO terms and KEGG pathways, and the Hub Genes with the highest connectivity in each module were identified. The Wilcoxon test was used to verify the expression level of hub genes between HCM and normal samples, and the "pROC" R package was used to verify the possibility of hub genes as biomarkers. Finally, the potential functions of hub genes were analyzed by GSEA software. RESULTS: Seven co-expression modules were constructed using sample clustering analysis. GO and KEGG enrichment analysis judged that the turquoise module is an important module. The hub genes of each module are RPL35A for module Black, FH for module Blue, PREI3 for module Brown, CREB1 for module Green, LOC641848 for module Pink, MYH7 for module Turquoise and MYL6 for module Yellow. The results of the differential expression analysis indicate that MYH7 and FH are considered true hub genes. In addition, the ROC curves revealed their high diagnostic value as biomarkers for HCM. Finally, in the results of the GSEA analysis, MYH7 and FH highly expressed genes were enriched with the "proteasome" and a "PPAR signaling pathway," respectively. CONCLUSIONS: The MYH7 and FH genes may be the true hub genes of HCM. Their respective enriched pathways, namely the "proteasome" and the "PPAR signaling pathway," may play an important role in the development of HCM.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) studied Hypertrophic cardiomyopathy (n=145). Hypertrophic cardiomyopathy vs. Normal controls was evaluated on Diagnostic value of hub genes as biomarkers for hypertrophic cardiomyopathy (MYH7 AUC: 0.762; FH AUC: 0.612, p=<0.05). Weighted gene co-expression network analysis identified MYH7 and FH as key diagnostic biomarkers for hypertrophic cardiomyopathy, with AUCs of 0.762 and 0.612, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: